0001209191-17-040978.txt : 20170619
0001209191-17-040978.hdr.sgml : 20170619
20170619211751
ACCESSION NUMBER: 0001209191-17-040978
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170615
FILED AS OF DATE: 20170619
DATE AS OF CHANGE: 20170619
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoCyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 510-775-0515
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAILEY DON M
CENTRAL INDEX KEY: 0001223697
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 17919714
MAIL ADDRESS:
STREET 1: 1300 N. KELLOGG DRIVE
STREET 2: SUITE D
CITY: ANAHEIM
STATE: CA
ZIP: 92607
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-06-15
0
0001642380
OncoCyte Corp
OCX
0001223697
BAILEY DON M
C/O ONCOCYTE CORPORATION
1010 ATLANTIC AVENUE, SUITE 102
ALAMEDA
CA
94501
1
0
0
0
Common Stock
247001
D
Option to Purchase Common Stock
5.10
2017-06-15
4
A
0
6520
0.00
A
2027-06-14
Common Stock
6520
6520
D
Option to Purchase Common Stock
5.10
2017-06-15
4
A
0
20000
0.00
A
2027-06-14
Common Stock
20000
20000
D
The shares are held by Mr. Bailey and his wife as co-trustees of a revocable trust, and in such capacity Mr. Bailey and his wife have shared voting and dispositive power over the shares.
Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018.
Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017.
/s/Don M. Bailey
2017-06-19